Key facts
- It has raised $11.3M across 2 recorded rounds; the latest was Seed Round ($1.5M) in May 2026.
- Notable investors include US National Science Foundation, MicroVentures, Ulu Ventures, SeedFolio, Guindy Alumni Angels — 15 tracked in total.
- Remedium Bio has filed 2 Form Ds with the SEC since 2021, most recently Aug 2024 ($4.4M sold to 26 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Remedium Bio
Funding rounds
2 roundsAbout Remedium Bio
Developer of gene therapies intended to come up with treatments for a broad range of diseases. The company's specialized gene therapy combines proven technologies in novel ways and their pipeline products include treatments in the fields of endocrinology, cardiology, and hematology, enabling patients to receive access to several therapeutic therapies for immune and age-related conditions.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2020
- Employees
- 14
- Website
- remedium-bio.com/
- Ownership
- Privately Held (backing)
Remedium Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Remedium Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Remedium Bio in its N-PORT filings yet. We sweep new filings monthly.